EducationJanuary 2026•6 min read
Understanding Phase 3 Trials: The Path to FDA Approval
In 2025, the FDA approved 46 novel drugs. Learn how Phase 3 trials work and why they're the crucial final step before a treatment reaches patients.
Phase 3 clinical trials represent the final and most critical step before a new treatment can receive FDA approval. Understanding how they work can help you make informed decisions about participation.
The Clinical Trial Phases Explained
Phase 1: Safety Testing - Small groups (20-100 participants) - Focus on safety and dosage - Usually healthy volunteers
Phase 2: Efficacy Testing - Larger groups (100-300 participants) - Evaluates effectiveness - Monitors side effects
Phase 3: Confirmation - Large-scale studies (1,000-3,000+ participants) - Confirms effectiveness - Compares to existing treatments - Required for FDA approval
Why Phase 3 Matters
- Efficacy: The treatment works as intended
- Safety: Side effects are acceptable
- Superiority or Non-Inferiority: How it compares to existing options
What Phase 3 Participants Experience
- Receive either the experimental treatment or a comparator
- Undergo regular monitoring and assessments
- Contribute valuable data to medical science
- May gain early access to promising treatments
The Path from Trial to Approval
After successful Phase 3 results: 1. Sponsor submits New Drug Application (NDA) to FDA 2. FDA reviews all clinical data 3. Advisory committees may provide input 4. FDA makes approval decision 5. Treatment becomes available to patients
Current Phase 3 Opportunities
Many promising treatments are currently in Phase 3 trials, including new options for cancer, autoimmune diseases, and neurological conditions.